Immunotherapy in Cancer Clinical Oncology Society 2017
See what other conferences are available at www.browse.armchairmedical.tv
-
Opening Ceremony
-
Cancer immunotherapy & history Jonathan Cebon
-
Immunotherapy Hype or Hope Decidedly hope Matt Hellmann
-
A collusion of interests Hope, hype and science and the shaping of patient's expectations of treatment Ian Kerridge
-
Immunotherapy Hype and hope Panel discussion
-
Prescribing errors in cancer treatment Dorothy Keefe
-
Peer review Matthew Links
-
Standards, governance and ICT the holy trinity for systemic therapies Liz Kenny & Marre Bransdon
-
Making medicine safe - lessons from Boeing, Hopkins & Tom Hanks Anthony Joshua
-
Patient Safety Deviation or deviant (human error, system or cultural failures)
-
Quality Proactive or reactive An Australian Perspective Prof Cliff Hughes AO
-
Evolution of quality based medicine How do we get from reactive to proactive Monika Krzyzanowska
-
Creating learning systems for quality and safety in cancer care Carrie Marr
-
Safe prescribing of chemotherapy Christine Carrington
-
Quality Proactive or Reactive A consumer perspective Grant Mundell
-
Quality Proactive or Reactive Panel Discussion
-
Using data to drive change in breast cancer care Tim Shaw
-
Implementing Cerner Oncology in a metropolitan cancer service the process and lessons learnt Richard Khor
-
An enterprise-wide analytics strategy to drive change in cancer care delivery and research Dana Rollison
-
Cancer Institute NSW’s vision for integrating data for cancer research the role of registries David Currow
-
Just where is data that is relevant to clinical teams hidden Building a useful map Emily Stone
-
Patient selection and biomarkers for immunotherapy in lung cancer Matthew D. Hellmann
-
Predicating response and resistance in drug therapy for advanced melanoma Prof Georgina Long
-
Predictive markers of response and resistance to immunotherapies in melanoma Prof Richard Scolyer
